#NWBO As a physician, there is several reasons why the idea of DCVax-L is exciting. #1. Patient compliance for medication in general is about 50-60%. The higher the side effect profile or burden of treatment, the lower the the compliance rate. DCVax-L immense advantage here.
You know who else hates side effects? Physicians. So when a treatment is given as an intradermal injection (high and known compliance) with such a low side effect profile, its something I am very excited about.
Dec 12, 2021 • 12 tweets • 2 min read
#NWBO, Re-reading 2018 DCVax-L interim results and actually took the time to look at the authors and where they are all from.
Liau - UCLA
Ashkan - King College
Tran - University of Floria
Campian - Washington University
Trusheim - Abbott NW Hospital
Cobbs - Swedish Medical Center
Heth - University of Michigan
Salacz - University of Kansas Cancer Center
D’Andre - Sutter Institute
Iwamoto - Columbia University
Dropcho - Indiana University Simon Cancer Center
Moshel - Overlook Medical Center
Walter - University of Rochester